Ensho Therapeutics has filed a notice of an exempt offering of securities to raise $20 Million in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Ensho Therapeutics is raising up to $20,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Ensho Therapeutics
Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases. The companys initial focus is on a pipeline of oral, selective small molecule inhibitors of lymphocyte homing integrin ?4?7 for IBD, a mechanism already validated by a commercially available antibody. Enshos assets were acquired from EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd., that is focused on gastrointestinal disease. Ensho is preparing to initiate a Phase 2 clinical program in UC with NSHO-101, the lead asset in the companys pipeline.
To learn more about Ensho Therapeutics, visit https://www.enshorx.com/
Ensho Therapeutics Linkedin Page: https://www.linkedin.com/company/enshorx/
Contact:
Danielle Fry, Chief Legal Officer and Chief Operating Officer
973-475-8970
https://www.linkedin.com/in/danielle-fry-b429809/
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.